[New medical therapy of neuroendocrine gastrointestinal tumors].
Eriksson
B
B
Medicinkliniken, Akademiska sjukhuset, Uppsala.
Janson
E T
ET
Skogseid
B
B
Oberg
K
K
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007414:Intestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D007421:Intestine, Small / Q000473:pathology; D009490:Neurosecretory Systems / Q000187:drug effects; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D015282:Octreotide
Ny medicinsk behandling av neuroendokrina gastrointestinala tumörer.